NASDAQ:ADIL Stock Quote
Adial Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of addiction and related disorders
The company is primarily engaged in the research and clinical development of its lead product candidate, which aims to reduce the risk of relapse in patients with alcohol use disorder. Adial utilizes a patient population-centric approach to address significant unmet medical needs in substance use disorders through its proprietary technology and scientific expertise. By leveraging partnerships and conducting clinical trials, Adial is committed to advancing solutions that improve the lives of individuals affected by addiction.
Frequently Asked Questions
Has Adial Pharmaceuticals partnered with other companies?
Yes, Adial Pharmaceuticals has pursued strategic partnerships with various organizations and institutions in the biopharmaceutical sector. These collaborations help to enhance their research capabilities, accelerate clinical development, and expand the reach of their products. Such partnerships often aim to share expertise, resources, and development costs associated with innovative drug development.
How does Adial Pharmaceuticals contribute to the community?
Adial Pharmaceuticals is committed to contributing to the community by addressing the critical issue of addiction through innovative treatments. The company often engages in awareness campaigns, educational initiatives, and research partnerships aimed at understanding and combating addiction, thereby enhancing public health and supporting those affected by substance use disorders.
How does Adial Pharmaceuticals engage with stakeholders?
Adial Pharmaceuticals actively engages with its stakeholders, including investors, healthcare professionals, and patients, through regular updates, investor presentations, and educational outreach. The company emphasizes transparency and communication, providing insights into their research progress and strategic directions while fostering partnerships within the healthcare community.
How does Adial Pharmaceuticals plan to achieve its mission?
Adial Pharmaceuticals plans to achieve its mission by focusing on rigorous clinical research, leveraging its experienced management team, and maintaining a strong pipeline of potential medications. With a commitment to scientific innovation, the company aims to produce effective treatment options while carefully navigating the regulatory pathways to ensure successful drug approval and commercialization.
How is Adial Pharmaceuticals funded?
Adial Pharmaceuticals is funded through a combination of equity financing, grants, and partnerships. The company has successfully raised capital through public offerings and private placements to support its clinical trials and operational expenses. In addition, it seeks funding through collaborations with research institutions and other pharmaceutical companies to further its research and development efforts.
What are Adial Pharmaceuticals' long-term goals?
Adial Pharmaceuticals' long-term goals include successfully bringing AD04 and additional pipeline products to market, establishing the company as a leader in the addiction treatment sector, and expanding its product offerings to cover a broader range of addictive disorders. The ultimate aim is to improve patient outcomes and provide innovative solutions to combat addiction.
What are some key milestones Adial Pharmaceuticals aims to achieve?
Key milestones for Adial Pharmaceuticals include completing pivotal clinical trials for AD04, receiving FDA approval for commercialization, and launching their lead product on the market. Additionally, the company aims to expand its drug pipeline by initiating new studies and developing other treatment candidates targeting addiction and related disorders.
What are the potential markets for Adial's products?
Adial Pharmaceuticals targets several substantial markets, primarily the burgeoning alcohol use disorder treatment market, valued at billions of dollars annually. Additionally, their research could extend into other addiction-related products, including treatments for opioid addiction, gambling addiction, and other behavioral disorders, thereby widening their potential market reach.
What are the risk factors for investing in Adial Pharmaceuticals?
Investing in Adial Pharmaceuticals, like any clinical-stage biotech firm, involves risk factors such as the uncertainties surrounding drug development, potential failure in clinical trials, dependence on regulatory approvals, and market competition. Investors should weigh these risks against the potential for high returns, especially if successful products make it to market.
What does Adial Pharmaceuticals see as the future of addiction treatment?
Adial Pharmaceuticals envisions a future where addiction treatment is more effective and personalized, with medications that are scientifically validated and can significantly improve patient quality of life. The company aims to lead advancements in this field, enabling healthcare providers to offer better options for individuals struggling with addiction, ultimately reducing the societal impacts of substance misuse.
What does Adial Pharmaceuticals, Inc. do?
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company primarily focused on developing and commercializing innovative therapies for addiction and related disorders. Their lead product candidate, AD04, is aimed at treating alcohol use disorder by modifying the way the brain responds to alcohol consumption. The company is dedicated to advancing its pipeline of products that target unmet medical needs in addiction treatment.
What is AD04?
AD04 is Adial Pharmaceuticals' lead drug candidate designed to treat alcohol use disorder. It is a novel oral medication that has been developed to assist individuals in reducing alcohol consumption and managing withdrawal symptoms. The drug acts on specific neurotransmitter systems to modify alcohol's effects, potentially helping patients regain control over their drinking habits.
What is Adial Pharmaceuticals' approach to clinical trials?
Adial Pharmaceuticals employs a rigorous and systematic approach to clinical trials, focusing on designing studies that effectively test the efficacy and safety of its drug candidates. The company collaborates with experienced clinical researchers and follows Good Clinical Practice (GCP) guidelines to ensure that trials are conducted ethically and yield credible data that can support regulatory submissions.
What is the significance of the Nasdaq listing for Adial Pharmaceuticals?
Being listed on the Nasdaq provides Adial Pharmaceuticals with enhanced visibility and credibility in the financial markets, facilitating easier access to capital for research and development. It also allows the company to attract institutional investors and improves liquidity for shareholders, which can support the company's ability to fund its projects and expand its operations.
What makes Adial Pharmaceuticals unique?
Adial Pharmaceuticals distinguishes itself by focusing exclusively on developing medications for addiction and related disorders, an area that is often underfunded and overlooked. Its innovative approach, including proprietary drug candidates like AD04, aims to address the growing crisis of addiction with scientifically backed therapies and a strong emphasis on patient outcomes.
What regulatory approvals has Adial Pharmaceuticals received?
Adial Pharmaceuticals has received regulatory approvals from the U.S. Food and Drug Administration (FDA) for their clinical trial protocols, allowing them to conduct studies on AD04 and other drug candidates. They are working towards obtaining the necessary approvals for market authorization based on the outcomes of their pivotal trials, which are essential for commercialization.
What stage is AD04 currently in?
AD04 is currently in late-stage clinical development, having completed Phase 2 clinical trials and recently initiating its Phase 3 pivotal trial. This crucial stage aims to confirm the efficacy and safety of the treatment in a larger population. Successful outcomes from this trial will pave the way for regulatory submissions and potential commercialization.
Where is Adial Pharmaceuticals headquartered?
Adial Pharmaceuticals is headquartered in Charlottesville, Virginia. This location serves as the central hub for its operations, including clinical research, corporate management, and strategic initiatives aimed at addressing the needs associated with addiction treatment and therapy development.
Who are the key executives at Adial Pharmaceuticals?
Key executives at Adial Pharmaceuticals include Dr. William Stilley, the CEO; Dr. Michael E. Ehlers, the Chief Scientific Officer; and Dr. Timothy E. Hodge, the Chief Financial Officer. Together, this team brings extensive experience in pharmaceutical development, investment, and management to guide the company in its mission to innovate in addiction treatment.
What is the current price of Adial Pharmaceuticals, Inc - Common Stock?
The current price of Adial Pharmaceuticals, Inc - Common Stock is 0.6900
When was Adial Pharmaceuticals, Inc - Common Stock last traded?
The last trade of Adial Pharmaceuticals, Inc - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Adial Pharmaceuticals, Inc - Common Stock?
The market capitalization of Adial Pharmaceuticals, Inc - Common Stock is 14.01M
How many shares of Adial Pharmaceuticals, Inc - Common Stock are outstanding?
Adial Pharmaceuticals, Inc - Common Stock has 20.30M shares outstanding.